Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) EBITDA (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed EBITDA for 16 consecutive years, with $118000.0 as the latest value for Q4 2025.

  • Quarterly EBITDA fell 82.26% to $118000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.5 million through Dec 2025, down 28.93% year-over-year, with the annual reading at $11.5 million for FY2025, 28.93% down from the prior year.
  • EBITDA for Q4 2025 was $118000.0 at Gyre Therapeutics, down from $6.9 million in the prior quarter.
  • The five-year high for EBITDA was $51.5 million in Q2 2022, with the low at -$91.6 million in Q4 2023.
  • Average EBITDA over 5 years is -$5.9 million, with a median of $1.4 million recorded in 2024.
  • The sharpest move saw EBITDA plummeted 342.74% in 2021, then skyrocketed 358.76% in 2022.
  • Over 5 years, EBITDA stood at -$20.3 million in 2021, then fell by 10.57% to -$22.5 million in 2022, then crashed by 307.98% to -$91.6 million in 2023, then soared by 100.73% to $665000.0 in 2024, then crashed by 82.26% to $118000.0 in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at $118000.0, $6.9 million, and $2.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.